Kasugamycin is a novel chitinase 1 inhibitor with strong antifibrotic effects on pulmonary fibrosis
J.-H. Lee, C.-M. Lee, J. H. Lee, M.-O. Kim, J. W. Park, S. Kamle, B. Akosman, E. L. Herzog, X. Y. Peng, J. A. Elias, C. G. Lee
This study identifies Kasugamycin as a novel CHIT1 inhibitor with strong antifibrotic effects in pulmonary fibrosis models.
bioRxiv · Feb 25, 2021Immunology